On 02 July 2026, Nanjing Leads Biolabs Co., Ltd. filed its Monthly Return for the period ended 30 June 2026 with Hong Kong Exchanges and Clearing Limited, detailing a sizeable realignment of its share structure.

Key developments 1. Conversion of unlisted shares: On 4 June 2026, 44.39 million unlisted domestic shares were converted into H shares, increasing the company’s outstanding H-share count by 28.96% to 197.67 million. The pool of unlisted shares fell to 1.22 million.

2. Authorised share capital enlarged: Total authorised/registered capital rose by the same 44.39 million shares to 198.89 million shares, each with a par value of RMB 1, reflecting the full impact of the conversion.

3. Equity incentive issuance: Within the month’s movements, 9.94 million new H shares were issued under the company’s H Share Award Scheme approved on 17 December 2025; these shares formed part of the overall conversion described above.

4. Public-float compliance affirmed: Leads Biolabs confirmed that, following the share conversion, it continues to meet the Main Board’s minimum 25% public-float requirement.

As at 30 June 2026, Leads Biolabs had no treasury shares and reported total issued share capital of 197.67 million H shares and 1.22 million remaining unlisted shares.